Paglalarawan

The non-small cell lung cancer (NSCLC) drug market in China in terms of revenue is set to grow by US$ 13 billion during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 17.1% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix.

Ang ulat ay nagbibigay ng napapanahong data ng laki ng merkado para sa panahon 2017-2020 at forecast na 2027 covering key market aspects like sales value for non-small cell lung cancer (NSCLC) drug. The China non-small cell lung cancer (NSCLC) drug market is segmented on the basis of type, incidence of gene mutation. Ayon sa uri, it is categorized into adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, squamous-cell carcinoma, at iba pa. By incidence of gene mutation, the non-small cell lung cancer (NSCLC) drug market is divided into ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homologue), at iba pa.

The report has profiled some of the key players of the market such as AstraZeneca plc., Betta Pharmaceuticals Co. Ltd., Bristol-Myers Squibb Company, Merck KGaA, Novartis International AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Co. Ltd.

Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the non-small cell lung cancer (NSCLC) drug market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

Saklaw ng Ulat

Uri ng: adenocarcinoma, large cell carcinoma, sarcomatoid carcinoma, squamous-cell carcinoma, at iba pa
Incidence of gene mutation: ALK (anaplastic lymphoma kinase), EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homologue), at iba pa
Mga Taon na Itinuturing: Ang ulat na ito ay sumasaklaw sa panahon 2017 sa 2027

Mga Pangunahing Benepisyo para sa mga Stakeholder

Get a comprehensive picture of the China non-small cell lung cancer (NSCLC) drug market
Pinpoint ang mga sektor ng paglago at mga trend para sa pamumuhunan
Understand what the future of the non-small cell lung cancer (NSCLC) drug market in China looks like
Kilalanin ang mapagkumpitensya na landscape at window ng pagkakataon

Talaan ng mga Nilalaman

1. Kahulugan ng Market
2. Metodolohiya ng Pananaliksik
3. Market Data & Outlook
3.1 Halaga ng Market
3.2 Pagtataya ng Halaga sa Market
4. Non-Small Cell Lung Cancer (NSCLC) Drug Market by Type
4.1 Adenocarcinoma
4.2 Large Cell Carcinoma
4.3 Sarcomatoid Carcinoma
4.4 Squamous-Cell Carcinoma
4.5 Ang iba naman
5. Non-Small Cell Lung Cancer (NSCLC) Drug Market by Incidence Of Gene Mutation
5.1 Alk (Anaplastic Lymphoma Kinase)
5.2 Egfr (Epidermal Growth Factor Receptor)
5.3 Kras (Kirsten Rat Sarcoma Viral Oncogene Homologue)
5.4 Ang iba naman
6. Mga Profile ng Kumpanya
6.1 AstraZeneca plc.
6.2 Betta Pharmaceuticals Co., Ltd.
6.3 Bristol-Myers Squibb Company
6.4 Merck KGaA
6.5 Novartis International AG
6.6 Pfizer, Inc.
6.7 Roche Holding AG
6.8 Takeda Pharmaceutical Co. Ltd.
7. Apendiks
7.1 Tungkol sa StrategyHelix
7.2 Pagtanggi